What question did this study set out to answer?

To identify AML cases likely to benefit from menin inhibition and evaluate targetable co-mutations.

December 8, 2025BloodOpen Access

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

View Full Paper

Ask AI

Bookmark

Authors

Randomised trial indicates potential for menin inhibitors in AML with genetic aberrations, highlighting combination therapy opportunities.

To identify AML cases likely to benefit from menin inhibition and evaluate targetable co-mutations.
Enrolled 13,458 adult patients diagnosed with de novo AML.
Examined samples via cytomorphology, cytogenetics, FISH, and RT-PCR.
Performed whole genome sequencing on a subset of 769 patients.
29% of patients showed genetic aberrations eligible for menin inhibitors.
Identified high frequency of targetable co-mutations in NPM1 and KMT2A cases.
KMT2A-PTD cases share co-mutation patterns with NPM1m, differing from KMT2Ar findings.

Irene Fuhrmann (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomised trial indicates potential for menin inhibitors in AML with genetic aberrations, highlighting combination therapy opportunities.

To identify AML cases likely to benefit from menin inhibition and evaluate targetable co-mutations.
Enrolled 13,458 adult patients diagnosed with de novo AML.
Examined samples via cytomorphology, cytogenetics, FISH, and RT-PCR.
Performed whole genome sequencing on a subset of 769 patients.
29% of patients showed genetic aberrations eligible for menin inhibitors.
Identified high frequency of targetable co-mutations in NPM1 and KMT2A cases.
KMT2A-PTD cases share co-mutation patterns with NPM1m, differing from KMT2Ar findings.

Irene Fuhrmann (2025) studied this question.

View Full Paper

Ask AI

Bookmark